{"id":"NCT00035815","sponsor":"Mayo Clinic","briefTitle":"Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial","officialTitle":"Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-06","primaryCompletion":"2007-08","completion":"2007-12","firstPosted":"2002-05-07","resultsPosted":"2013-02-15","lastUpdate":"2013-02-15"},"enrollment":330,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Insulin like growth factor, type 1","otherNames":["Mycotrophin"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"IGF-1","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.","primaryOutcome":{"measure":"Rate of Change in Composite Manual Muscle Testing (MMT) Score","timeFrame":"Baseline and 24 months","effectByArm":[{"arm":"IGF-1","deltaMin":0.44,"sd":0.57},{"arm":"Placebo","deltaMin":0.39,"sd":0.39}],"pValues":[{"comp":"OG000 vs OG001","p":"0.529"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":20,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["19822878","19029516"],"seeAlso":["http://www.alsa.org"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":167},"commonTop":["Depression","Site reactions","Respiratory failure","Headache","Change in visual acuity"]}}